CD274 and non-small cell lung carcinoma: In recent years, the introduction of immune checkpoint inhibitors (ICIs) has changed the therapeutic landscape of NSCLC, especially programmed death receptor-1 (PD-1) and its ligand (PD-L1) blockers (5, 6).